Caris Life Sciences Inc (CAI)

$16.76 +0.82 (5.14%)
Market Cap 4.51B
Revenue (ttm) 812.03M
Net Income (ttm) -68.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 134.58
Profit Margin -8.39%
Debt to Equity Ratio 0.64
Volume 3,277,500
Avg Vol 2,390,884
Day's Range N/A - N/A
Shares Out 282.65M
Stochastic %K 24%
Beta N/A
Analysts Strong Sell
Price Target $28.00

Company Profile

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions;...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 771 8946
Fax: 866 479 4925
Address:
750 West John Carpenter Freeway, Suite 800, Irving, United States
MarketBeat
MarketBeat May. 13 at 9:07 AM
https://marketbeat.com/a/8651704/ $CAI Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
0 · Reply
Jasooon
Jasooon May. 12 at 2:03 PM
$CAI hello
0 · Reply
Ron12341
Ron12341 May. 12 at 1:25 PM
$CAI Insider purchase at 16.15. Always good to see
0 · Reply
prodigy81
prodigy81 May. 11 at 5:40 PM
$CAI I thought this one is pretty solid so I recently jump into. But may be because of that, this is down. lol
2 · Reply
Jasooon
Jasooon May. 9 at 1:09 AM
$CAI great ER results you
0 · Reply
appayip
appayip May. 8 at 5:14 PM
$CAI Natera has revenue around $2,3 billion, growth ~%30 and market cap ~30 billion, 13-14x. Caris will make $1 billion, growth ~%25, market cap is 5,6 billion. And caris has huge dataset of millions of tests + early detection test is on its way. I added to my position today.
0 · Reply
girishw
girishw May. 8 at 1:09 AM
$CAI Guys, this company is a Walmart in molecular profiling. It has about 285M shares outstanding. There is no way that this company stays at this price. The first question that BOFA analyst asked was whether they were going to make 20% Year over Year growth, which now seems practically not possible. They guided 1.03B which leaves them to generate 800M in 3 quarters. They are also very not focused on increasing sales rep count aggressively. One of the analyst compared them with GH, which has 800 in sales and marketing. GH always for the past has invested with high Opex,which this company shy's away . CEO is operating like a family owned business and not like how Wall street wants. Just compare the volume from Quarter to Quarter not considering the true ups. This company is going no-where. Sad, that I brought the shares early, I am stuck with holding them atleast until I get out at no-profit and no-loss, Good luck longs. The earnings was highly disappointing. CEO and C-suite team should be
2 · Reply
Eskayes
Eskayes May. 7 at 11:40 PM
$CAI nobody cares about profitability here, least alone the CEO. Just growth. Then sell. Everyone knows he’s an operator looking to exit
0 · Reply
Damian23
Damian23 May. 7 at 9:27 PM
$CAI When this companies sell off when they are at the lows we have to find out what the market does not like here, that is crucial to not underperform, I think it is the SBC and poor profitability, add this up to strong competition and then you have it.
0 · Reply
Ron12341
Ron12341 May. 7 at 9:26 PM
$CAI No justification for this ridiculous drop.
0 · Reply
Latest News on CAI
Caris Life Sciences Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 1:00 PM EDT - 19 hours ago

Caris Life Sciences Transcript: Bank of America Global Healthcare Conference 2026

Caris Life Sciences announces publication of study on measuring TMB using WES

2026-05-11T17:55:47.000Z - 1 day ago

Caris Life Sciences announces publication of study on measuring TMB using WES

Caris Life Sciences submits application to NYSDOH for Caris Assure testing

2026-05-08T23:01:06.000Z - 4 days ago

Caris Life Sciences submits application to NYSDOH for Caris Assure testing

Caris Life Sciences price target lowered to $22 from $28 at Baird

2026-05-08T16:53:15.000Z - 4 days ago

Caris Life Sciences price target lowered to $22 from $28 at Baird

Caris Life Sciences price target lowered to $32 from $38 at BTIG

2026-05-08T13:03:25.000Z - 4 days ago

Caris Life Sciences price target lowered to $32 from $38 at BTIG

Caris Life Sciences price target lowered to $30 from $35 at JPMorgan

2026-05-08T12:26:11.000Z - 4 days ago

Caris Life Sciences price target lowered to $30 from $35 at JPMorgan

Caris Life Sciences price target lowered to $28 from $35 at Citi

2026-05-08T11:34:07.000Z - 5 days ago

Caris Life Sciences price target lowered to $28 from $35 at Citi

Caris Life Sciences reports Q1 EPS 0c, consensus (2c)

2026-05-07T21:18:19.000Z - 5 days ago

Caris Life Sciences reports Q1 EPS 0c, consensus (2c)

Caris Life Sciences still sees 2026 revenue $1.0B-$1.02B, consensus $1.01B

2026-05-07T21:17:18.000Z - 5 days ago

Caris Life Sciences still sees 2026 revenue $1.0B-$1.02B, consensus $1.01B

Caris Life Sciences Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 5 days ago

Caris Life Sciences Earnings Call Transcript: Q1 2026

Caris Life Sciences’ ChromoSeq receives MolDX approval

2026-05-04T13:08:37.000Z - 8 days ago

Caris Life Sciences’ ChromoSeq receives MolDX approval

Caris Life Sciences initiated with a Buy at Jefferies

2026-04-12T23:45:06.000Z - 4 weeks ago

Caris Life Sciences initiated with a Buy at Jefferies

Caris Life Sciences initiated with a Neutral at Piper Sandler

2026-04-10T08:50:43.000Z - 4 weeks ago

Caris Life Sciences initiated with a Neutral at Piper Sandler

Caris Life Sciences price target lowered to $30 from $34 at Evercore ISI

2026-04-06T12:22:20.000Z - 5 weeks ago

Caris Life Sciences price target lowered to $30 from $34 at Evercore ISI

Caris Life Sciences launches Caris ChromoSeq tumor profiling assay

2026-04-02T12:43:00.000Z - 5 weeks ago

Caris Life Sciences launches Caris ChromoSeq tumor profiling assay

Caris Life Sciences initiated with a Buy at Goldman Sachs

2026-04-01T09:15:47.000Z - 6 weeks ago

Caris Life Sciences initiated with a Buy at Goldman Sachs

Caris Life Sciences announces finalized Achieve 1 Study results

2026-03-31T22:05:52.000Z - 6 weeks ago

Caris Life Sciences announces finalized Achieve 1 Study results

Caris Life Sciences announces publication of study on GPSai algorithm

2026-03-20T12:35:13.000Z - 7 weeks ago

Caris Life Sciences announces publication of study on GPSai algorithm

Caris Life Sciences introduces new Caris AI Insights

2026-03-16T12:40:47.000Z - 2 months ago

Caris Life Sciences introduces new Caris AI Insights

Caris Life Sciences price target lowered to $22 from $30 at Canaccord

2026-03-13T11:05:42.000Z - 2 months ago

Caris Life Sciences price target lowered to $22 from $30 at Canaccord

Caris Life Sciences price target raised to $28 from $26 at Baird

2026-03-02T12:45:06.000Z - 2 months ago

Caris Life Sciences price target raised to $28 from $26 at Baird

Caris Life Sciences price target lowered to $34 from $38 at Evercore ISI

2026-02-27T13:22:00.000Z - 2 months ago

Caris Life Sciences price target lowered to $34 from $38 at Evercore ISI

Caris Life Sciences Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 2 months ago

Caris Life Sciences Earnings Call Transcript: Q4 2025

Caris Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 4 months ago

Caris Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Caris Life Sciences Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 6 months ago

Caris Life Sciences Earnings Call Transcript: Q3 2025

Caris Life Sciences Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Caris Life Sciences Earnings Call Transcript: Q2 2025

Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering

May 23, 2025, 5:54 PM EDT - 1 year ago

Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering

Caris Life Sciences discloses rise in revenue in US IPO filing

May 23, 2025, 5:12 PM EDT - 1 year ago

Caris Life Sciences discloses rise in revenue in US IPO filing

Oncology precision medicine platform Caris Life Sciences files for an estimated $300 million IPO

May 23, 2025, 4:22 PM EDT - 1 year ago

Oncology precision medicine platform Caris Life Sciences files for an estimated $300 million IPO

Caris Life Sciences IPO Registration Document (S-1)

May 23, 2025, 3:27 PM EDT - 1 year ago

Caris Life Sciences IPO Registration Document (S-1)

MarketBeat
MarketBeat May. 13 at 9:07 AM
https://marketbeat.com/a/8651704/ $CAI Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
0 · Reply
Jasooon
Jasooon May. 12 at 2:03 PM
$CAI hello
0 · Reply
Ron12341
Ron12341 May. 12 at 1:25 PM
$CAI Insider purchase at 16.15. Always good to see
0 · Reply
prodigy81
prodigy81 May. 11 at 5:40 PM
$CAI I thought this one is pretty solid so I recently jump into. But may be because of that, this is down. lol
2 · Reply
Jasooon
Jasooon May. 9 at 1:09 AM
$CAI great ER results you
0 · Reply
appayip
appayip May. 8 at 5:14 PM
$CAI Natera has revenue around $2,3 billion, growth ~%30 and market cap ~30 billion, 13-14x. Caris will make $1 billion, growth ~%25, market cap is 5,6 billion. And caris has huge dataset of millions of tests + early detection test is on its way. I added to my position today.
0 · Reply
girishw
girishw May. 8 at 1:09 AM
$CAI Guys, this company is a Walmart in molecular profiling. It has about 285M shares outstanding. There is no way that this company stays at this price. The first question that BOFA analyst asked was whether they were going to make 20% Year over Year growth, which now seems practically not possible. They guided 1.03B which leaves them to generate 800M in 3 quarters. They are also very not focused on increasing sales rep count aggressively. One of the analyst compared them with GH, which has 800 in sales and marketing. GH always for the past has invested with high Opex,which this company shy's away . CEO is operating like a family owned business and not like how Wall street wants. Just compare the volume from Quarter to Quarter not considering the true ups. This company is going no-where. Sad, that I brought the shares early, I am stuck with holding them atleast until I get out at no-profit and no-loss, Good luck longs. The earnings was highly disappointing. CEO and C-suite team should be
2 · Reply
Eskayes
Eskayes May. 7 at 11:40 PM
$CAI nobody cares about profitability here, least alone the CEO. Just growth. Then sell. Everyone knows he’s an operator looking to exit
0 · Reply
Damian23
Damian23 May. 7 at 9:27 PM
$CAI When this companies sell off when they are at the lows we have to find out what the market does not like here, that is crucial to not underperform, I think it is the SBC and poor profitability, add this up to strong competition and then you have it.
0 · Reply
Ron12341
Ron12341 May. 7 at 9:26 PM
$CAI No justification for this ridiculous drop.
0 · Reply
prodigy81
prodigy81 May. 7 at 8:50 PM
$CAI Intial one starts here today. But why is this down today?
1 · Reply
prodigy81
prodigy81 May. 7 at 8:27 PM
$CAI $BLLN $GRAL Do they have common in cancer diagonisic area right?
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 8:21 PM
$CAI Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.00 • Reported revenue of $216.17M up 78.78% YoY • Caris Life Sciences reaffirms full year 2026 revenue guidance of $1B to $1.02B, representing 23% to 26% growth, and expects clinical therapy selection volume growth of approximately 20% compared to full year 2025.
0 · Reply
SuperGreenToday
SuperGreenToday May. 7 at 11:42 AM
$CAI Share Price: $19.15 Contract Selected: Oct 16, 2026 $20 Calls Buy Zone: $2.75 – $3.39 Target Zone: $4.50 – $5.50 Potential Upside: 55% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
appayip
appayip May. 5 at 8:25 PM
$TEM is red, while $CAI is green. any ideas why? i dont complain, i sold TEM and bought CAI long ago, i am just curious.
0 · Reply
Damian23
Damian23 Apr. 15 at 10:24 AM
$TEM Im bullish on both but don't sleep on $CAI , I don't really know why the divergence in followers between these 2, although TEM is more diversified, CAI is best in class as well. I hope they both double by end of year.
2 · Reply
CromieAds
CromieAds Apr. 14 at 10:04 PM
$CAI will be a triple digit stock once the multi early detection cancer test progresses. It’s the best available today and available soon (first half of 2026)
0 · Reply
Ron12341
Ron12341 Apr. 14 at 2:05 AM
$CAI waiting for this to take off… Good analyst coverage lately
1 · Reply
notreload_ai
notreload_ai Apr. 13 at 4:04 PM
Canaccord says $BHVN is undervalued and could rise on epilepsy trial results. Jefferies likes $CAI and $VCYT , citing strong growth in cancer diagnostics and solid finances. https://notreload.xyz/xy/analysts-turn-bullish-on-biohaven-caris-and-veracyte/
0 · Reply
prismmarketview
prismmarketview Apr. 9 at 12:08 PM
$CAI Caris Life Sciences rolled out a multimodal AI signature for NSCLC that tells you when to add chemo to IO—and when to avoid it. Same WES/WTS data backbone as their other Caris AI Insights, but now aimed directly at chemo harm vs benefit. @carisls #Chemotherapy #Oncology https://prismmarketview.com/caris-launches-ai-tool-to-show-when-chemo-helps-or-hurts-lung-cancer-patients/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 8 at 4:12 PM
$CAI RSI: 57.49, MACD: -0.2924 Vol: 0.74, MA20: 18.53, MA50: 20.03 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CromieAds
CromieAds Apr. 2 at 7:29 PM
$CAI https://www.prnewswire.com/news-releases/caris-life-sciences-announces-launch-of-caris-chromoseq-the-worlds-first-whole-genome-and-whole-transcriptome-tumor-profiling-assay-for-myeloid-malignancies-302732465.html
0 · Reply